Answers are grounded in this paper and cite their sources.
Background: The incidence and risk factors for central nervous system (CNS) metastases in soft tissue sarcoma (STS) are poorly defined. We evaluated the frequency of CNS metastases in STS and associated clinicopathologic and genomic factors. Methods: This retrospective study used the Memorial Sloan Kettering Cancer Center institutional cBioPortal database. Patients with invasive STS, including gastrointestinal stromal tumor, were included. CNS metastases were identified using natural language processing-derived radiology annotations and confirmed by manual chart review. Cumulative incidence was estimated with death as a competing event. Clinicopathologic and genomic associations were evaluated using Firth logistic regression with correction for multiplicity; post-CNS metastasis survival was estimated using Kaplan–Meier analysis. Results: A total of 5379 patients were included. CNS metastases were identified in 161 patients (3.0%), with a 10-year cumulative incidence of 4.5% after accounting for death as a competing event. Median overall survival after CNS metastasis was 4.76 months (95% CI, 3.9–7.5). In one-versus-rest analyses, increased odds of CNS metastasis were observed for alveolar soft part sarcoma (OR 16.61, 95% CI 7.21–35.81; q < 0.001), rhabdomyosarcoma (OR 2.44, 95% CI 1.42–3.97; q = 0.007), non-uterine leiomyosarcoma (OR 2.24, 95% CI 1.45–3.34; q = 0.003), extremity primaries (OR 2.20, 95% CI 1.58–3.05; q < 0.001), head and neck primaries (OR 2.11, 95% CI 1.26–3.35; q = 0.017), and PDGFRB alterations (OR 4.90, 95% CI 2.29–9.41; q = 0.016). KIT alterations were associated with lower odds (OR 0.10, 95% CI 0.02–0.29; q < 0.001). Conclusions: CNS metastases in STS were uncommon but associated with poor survival, with risk varying by histology and primary site.
No takes yet. Share an insight, caveat, or question.
Shahnam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: